TITUSVILLE, N.J., Aug. 28 /PRNewswire/ -- Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced that it will appeal yesterday's decision by the U.S. District Court of Delaware, which ruled the patent for RAZADYNE(R) (galantamine hydrobromide) is invalid.
The decision allows FDA-approved generic versions of immediate-release galantamine hydrobromide to enter the U.S. marketplace "at risk" pending an appeal. A favorable ruling would have provided patent protection for RAZADYNE(R) IR until the patent expires on December 14, 2008.
"We are disappointed by the court's decision and will appeal this ruling," said Janet Vergis, President of Janssen and Ortho-McNeil Neurologics. "We believe the patent protecting RAZADYNE(R) is valid and would be infringed by the introduction of a generic galantamine hydrobromide product."
Barr Laboratories and AlphaPharm Pty Ltd. filed Abbreviated New Drug Applications ("ANDAs") to market galantamine hydrobromide before the expiration of the patent, claiming the patent was invalid. Janssen, Janssen Pharmaceutica N.V., and patent owner Synaptech Inc. filed a patent infringement complaint against Barr and AlphaPharm in June 2005. Other lawsuits against generic companies seeking to market galantamine hydrobromide before the expiration of the patent are bound by the outcome of this case.
RAZADYNE and RAZADYNE ER are marketed by Ortho-McNeil Neurologics in the United States, and are indicated in the treatment of mild to moderate dementia of the Alzheimer's type.
Important Safety Information
In clinical trials, the most common side effects are nausea, vomiting,
diarrhea, loss of appetite and weight loss. Typically, these side effects
are mild and temporary. RAZADYNE(R) and RAZADYNE(R) ER may not be for
everyone. Some people experience a slowed heart rate, which may lead to
fainting. Serious stomach problems can occur in people taking medications
such as nonsteroid
|SOURCE Ortho-McNeil Neurologics|
Copyright©2008 PR Newswire.
All rights reserved